U.S. politician’s super suspicious Palantir stock trade gains 30% in less than 3 months

United States Senator John Boozman’s first reported purchase of Palantir (NASDAQ: PLTR) has drawn attention after the investment gained nearly 30% in less than three months.

Data shows that Boozman purchased Palantir shares on May 15, 2026, in a transaction valued between $1,001 and $15,000.

The trade was jointly owned and disclosed on June 16, about one month after it was executed. 

Since the purchase, Palantir stock has surged approximately 28.4%, significantly outperforming the SPDR S&P 500 ETF Trust (SPY), which gained about 4.6% over the same period.

At the time of the purchase, Palantir shares traded near $134. The stock remained volatile through June and July, briefly dipping below $110 before recovering and surging from the mid-$120s to trade at $172 as of press time.

The timing of the Senate trade is notable because Boozman serves on the Senate Appropriations Committee and its Defense Subcommittee, which oversees federal defense spending.

Notably, Palantir is one of the largest U.S. government software contractors, providing data analytics and artificial intelligence platforms to defense, intelligence, and national security agencies.

Palantir stock rallies on record earnings 

The recent rebound followed the company’s second-quarter earnings report, which exceeded Wall Street expectations across key metrics. 

Revenue reached approximately $1.94 billion, up 93% year-over-year. U.S. commercial revenue jumped 149% to $764 million, while U.S. government revenue increased roughly 90%.

Management also raised full-year 2026 revenue guidance to between $8.15 billion and $8.16 billion, implying annual growth of about 82%.

At the same time, the company reported adjusted free cash flow margins above 60%, maintained a debt-free balance sheet, and ended the quarter with a substantial cash position.

Meanwhile, the May 15 transaction marked Boozman’s first reported purchase of the technology stock. 

Although the investment was relatively small, it has reignited debate over congressional stock trading, particularly when lawmakers invest in companies tied to sectors they oversee. 

While there is no evidence of wrongdoing or misuse of non-public information, and the trade was disclosed under the STOCK Act, critics argue such investments can create the appearance of a conflict of interest when they involve major government contractors.